U.S. Markets close in 1 hr 54 mins

Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

Stock Monitor: Bovie Medical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Valeritas Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Details of the Studies Presented

  • Short-term Evaluation Demonstrates Improved Glycemic Control with New Insulin Delivery Device: This three-month evaluation was conducted in 60 patients with type-2 diabetes across multiple endocrine clinics within the Southern California Kaiser Permanente Group to study if simplifying insulin delivery with a new insulin delivery device (V-Go) resulted in improved glycemic control in patients who were uncontrolled on prior regimens. After three months of V-Go use, significant reductions were observed in both A1C and TDD. Improvements in A1C were noted across a wide range of baseline insulin doses (30 to 200 U/day). Prior to initiating V-Go, 60% of patients exhibited poor glycemic control which was reduced to 22% of patients with use of V-Go.
  • 24-Hour Wearable Basal-Bolus Insulin Delivery Device Improves Time in Range and Treatment Satisfaction over Multiple Daily Injections-A Pilot Study: This prospective pilot study used continuous glucose monitoring technology to compare blood glucose time in range for an insulin regimen consisting of three or more insulin injections/day to time in range after switching to V-Go for basal-bolus insulin delivery. Blood glucose time in range (80 to 140 mg/dl) was evaluated using CGM in seven patients diagnosed with type-2 diabetes on stable doses of three or more insulin injections/day and after five weeks of V-Go use. After switching to V-Go, the average time in range for all patients increased by 35% and insulin TDD decreased by 39% from 97 to 59 U/day compared to baseline insulin therapy. On a patient basis, 6 out of 7 patients experienced improved time in range. In these six patients, average time in range increased by 49% and insulin TDD decreased from 83 to 56 U/day compared to baseline insulin therapy. Across all patients, treatment satisfaction scores were higher for V-Go compared to prior insulin therapy.

Post announcement of the news, shares of the Company surged in pre-market trade.

About V-Go® Wearable Insulin Delivery Device

V-Go® Wearable Insulin Delivery device, Valeritas' flagship product, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type-2 diabetes patients.

About Valeritas Holdings, Inc.

Founded in 2006 and headquartered in Bridgewater Township, New Jersey, Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

Stock Performance Snapshot

May 21, 2018 - At Monday's closing bell, Valeritas's stock fell 1.26%, ending the trading session at $1.57.

Volume traded for the day: 1.18 million shares, which was above the 3-month average volume of 667.39 thousand shares.

After yesterday's close, Valeritas's market cap was at $29.42 million.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was flat at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors